Long circulating half‐life and high tumor selectivity of the photosensitizer meta‐tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma

In a model of nude mice bearing a human colon carcinoma xenograft, the biodistribution and tumor localization of meta‐tetrahydroxyphenylchlorin (m‐THPC) coupled to polyethylene glycol (PEG) were compared with those of the free form of this photosensitizer used in photodynamic therapy (PDT). At different times after i.v. injection of both forms of 125I‐labeled photosensitizer, m‐THPC‐PEG gave on average a 2‐fold higher tumor uptake than free m‐THPC. In addition, at early times after injection, m‐THPC‐PEG showed a 2‐fold longer blood circulating half‐life and a 4‐fold lower liver uptake than free m‐THPC. The tumor to normal tissue ratios of radioactivity concentrations were always higher for m‐THPC‐PEG than for free m‐THPC at any time point studied from 2 to 96 hr post‐injection. Significant coefficients of correlation between direct fluorescence measurements and radioactivity counting were obtained within each organ tested. Fluorescence microscopy studies showed that m‐THPC‐PEG was preferentially localized near the tumor vessels, whereas m‐THPC was more diffusely distributed inside the tumor tissue. To verify whether m‐THPC‐PEG conjugate remained phototoxic in vivo, PDT experiments were performed 72 hr after injection and showed that m‐THPC‐PEG was as potent as free m‐THPC in the induction of tumor regression provided that the irradiation dose for m‐THPC‐PEG conjugate was adapted to a well‐tolerated 2‐fold higher level. The overall results demonstrate first the possibility of improving the in vivo tumor localization of a hydrophobic dye used for PDT by coupling it to PEG and second that a photosensitizer conjugated to a macromolecule can remain phototoxic in vivo. Int. J. Cancer 76:842–850, 1998.© 1998 Wiley‐Liss, Inc.

[1]  H Lenz,et al.  Measurements on the depth of penetration of light (0.35–1.0 µm) in tissue , 1977, Radiation and environmental biophysics.

[2]  G. Wagnières,et al.  Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi , 1995, Cancer.

[3]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[4]  Daniel Braichotte,et al.  Clinical pharmacokinetic studies of tetra(meta‐hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths , 1995, International journal of cancer.

[5]  T. Berg,et al.  Uptake, intracellular transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes. , 1992, The Journal of biological chemistry.

[6]  T. Dougherty,et al.  CARBON‐14 LABELING AND BIOLOGICAL ACTIVITY OF THE TUMOR‐LOCALIZING DERIVATIVE OF HEMATOPORPHYRIN , 1988, Photochemistry and photobiology.

[7]  F. Buchegger,et al.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments. , 1989, The Journal of clinical investigation.

[8]  M C Berenbaum,et al.  Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. , 1989, The Biochemical journal.

[9]  H. Altermatt,et al.  Photodynamic therapy with m‐tetrahydroxyphenylchlorin in vivo: Optimization of the therapeutic index , 1993, International journal of cancer.

[10]  M. Siciliano,et al.  Longitudinal karyotype and genetic signature analysis of cultured human colon adenocarcinoma cell lines LS180 and LS174T. , 1980, Cancer research.

[11]  R. Veenhuizen,et al.  Intraperitoneal photodynamic therapy in the rat: Comparison of toxicity profiles for photofrin and mTHPC , 1994, International journal of cancer.

[12]  J Moan,et al.  PHOTOCHEMOTHERAPY OF CANCER: EXPERIMENTAL RESEARCH , 1992, Photochemistry and photobiology.

[13]  F. Martin,et al.  Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid , 1992, International journal of cancer.

[14]  C. Gomer PRECLINICAL EXAMINATION OF FIRST and SECOND GENERATION PHOTOSENSITIZERS USED IN PHOTODYNAMIC THERAPY , 1991, Photochemistry and photobiology.

[15]  T. Hasan,et al.  Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. , 1994, British Journal of Cancer.

[16]  U Althaus,et al.  Effect of drug‐light interval on photodynamic therapy with meta‐tetrahydroxyphenylchlorin in malignant mesothelioma , 1993, International journal of cancer.

[17]  M C Berenbaum,et al.  In vivo biological activity of the components of haematoporphyrin derivative. , 1982, British Journal of Cancer.

[18]  L. Rudel,et al.  Characterization of plasma lipoproteins separated and purified by agarose-column chromatography. , 1974, The Biochemical journal.

[19]  R. Anderson,et al.  TRANSMITTANCE OF NONIONIZING RADIATION IN HUMAN TISSUES * , 1981, Photochemistry and photobiology.

[20]  T. Dougherty,et al.  HOW DOES PHOTODYNAMIC THERAPY WORK? , 1992, Photochemistry and photobiology.

[21]  C. Heusser,et al.  Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T J Dougherty,et al.  PHOTOSENSITIZERS: THERAPY AND DETECTION OF MALIGNANT TUMORS , 1987, Photochemistry and photobiology.

[23]  P. Monnier,et al.  Photofrin II Pharmacokinetics and Optical Dosing in Tissue: Apparatus and Clinical Measurements for the Pharynx, Esophagus, and Tracheobronchial Tree , 1991 .

[24]  M. C. Berenbaum,et al.  Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. , 1991, British journal of cancer.

[25]  F. Buchegger,et al.  Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeability , 1993, International journal of cancer.

[26]  B. Wilson,et al.  Light propagation in animal tissues in the wavelength range 375-825 nanometers. , 1984, Progress in clinical and biological research.

[27]  H. van den Bergh,et al.  Antibody–fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice , 1991, Cancer.

[28]  H. Barr,et al.  Photodynamic therapy with phthalocyanine sensitisation: quantitative studies in a transplantable rat fibrosarcoma. , 1987, British Journal of Cancer.

[29]  J. Moan,et al.  Tissue distribution of 3H-hematoporphyrin derivative and its main components, 67Ga and 131I-albumin in mice bearing Lewis lung carcinoma. , 1984, Progress in clinical and biological research.

[30]  H. Oppelaar,et al.  Photosensitizing efficacy of MTHPC‐PDT compared to Photofrin‐PDT in the RIF1 mouse tumour and normal skin , 2006, International journal of cancer.

[31]  J Moan,et al.  Evaluation of a new photosensitizer, meso‐tetra‐hydroxyphenyl‐chlorin, for use in photodynamic therapy: A comparison of its photobiological properties with those of two other photosensitizers , 1994, International journal of cancer.